122 related articles for article (PubMed ID: 1827854)
1. Photodynamic therapy of the canine peritoneum: normal tissue response to intraperitoneal and intravenous photofrin followed by 630 nm light.
Tochner Z; Mitchell JB; Hoekstra HJ; Smith P; DeLuca AM; Barnes M; Harrington F; Manyak M; Russo D; Russo A
Lasers Surg Med; 1991; 11(2):158-64. PubMed ID: 1827854
[TBL] [Abstract][Full Text] [Related]
2. Intravenous vs intraperitoneal sensitizer: implications for intraperitoneal photodynamic therapy.
Perry RR; Smith PD; Evans S; Pass HI
Photochem Photobiol; 1991 Mar; 53(3):335-40. PubMed ID: 1829531
[TBL] [Abstract][Full Text] [Related]
3. [Topical administration of hematoporphyrin derivative and red light irradiation. A therapeutic approach in psoriasis].
Monfrecola G; Mangone S; Procaccini EM; Santoianni P
G Ital Dermatol Venereol; 1988 Dec; 123(12):671-4. PubMed ID: 2978159
[No Abstract] [Full Text] [Related]
4. Comparison of fluorescence and photodynamic activities of whole hematoporphyrin derivative and its enriched active components.
Nelson JS; Wright WH; Berns MW
J Natl Cancer Inst; 1985 Dec; 75(6):1135-40. PubMed ID: 2933546
[TBL] [Abstract][Full Text] [Related]
5. A comparison of serum kinetics and tissue distribution of photofrin II following intravenous and intraperitoneal injection in the mouse.
Pantelides ML; Moore JV; Blacklock NJ
Photochem Photobiol; 1989 Jan; 49(1):67-70. PubMed ID: 2524073
[No Abstract] [Full Text] [Related]
6. Light dosimetry model for photodynamic therapy treatment planning.
Grossweiner LI
Lasers Surg Med; 1991; 11(2):165-73. PubMed ID: 1827855
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC.
Veenhuizen RB; Ruevekamp-Helmers MC; Helmerhorst TJ; Kenemans P; Mooi WJ; Marijnissen JP; Stewart FA
Int J Cancer; 1994 Dec; 59(6):830-6. PubMed ID: 7989125
[TBL] [Abstract][Full Text] [Related]
8. [Selective hematoporphyrin derivative (HMD) application in arterial vessels using a porous balloon catheter results in equivalent levels as compared to high-dose systemic administration].
Gonschior P; Erdemci A; Gerheuser F; Gonschior GM; Mack B; Kolbe T; Goetz AE; Höfling B
Z Kardiol; 1991 Dec; 80(12):738-45. PubMed ID: 1837968
[TBL] [Abstract][Full Text] [Related]
9. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative.
Berns MW; Rettenmaier M; McCullough J; Coffey J; Wile A; Berman M; DiSaia P; Weinstein G
Lasers Surg Med; 1984; 4(1):73-7. PubMed ID: 6235419
[TBL] [Abstract][Full Text] [Related]
10. Study of the in vivo and in vitro photosensitizing capabilities of uroporphyrin I compared to photofrin II.
Nelson JS; Sun CH; Berns MW
Lasers Surg Med; 1986; 6(2):131-6. PubMed ID: 2941630
[TBL] [Abstract][Full Text] [Related]
11. Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II.
Gibson SL; van der Meid KR; Murant RS; Hilf R
Br J Cancer; 1990 Apr; 61(4):553-7. PubMed ID: 2139578
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy of C3H mouse mammary carcinoma with haematoporphyrin di-ethers as sensitizers.
Evensen JF; Sommer S; Rimington C; Moan J
Br J Cancer; 1987 May; 55(5):483-6. PubMed ID: 2955805
[TBL] [Abstract][Full Text] [Related]
13. Verapamil and hematoporphyrin derivative for tumour destruction by photodynamic therapy.
Gossner L; Wittke H; Warzecha A; Sroka R; Ernst H; Meier M; Ell C
Br J Cancer; 1991 Jul; 64(1):84-6. PubMed ID: 1830212
[No Abstract] [Full Text] [Related]
14. Depth measurements and histopathological characterization of photodynamic therapy generated normal brain necrosis as a function of incident optical energy dose.
Dereski MO; Chopp M; Garcia JH; Hetzel FW
Photochem Photobiol; 1991 Jul; 54(1):109-12. PubMed ID: 1835100
[TBL] [Abstract][Full Text] [Related]
15. Use of hematoporphyrin in photodynamic therapy.
Dougherty TJ
J Photochem Photobiol B; 1991 Mar; 8(4):439. PubMed ID: 1828502
[No Abstract] [Full Text] [Related]
16. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin.
Savary JF; Monnier P; Fontolliet C; Mizeret J; Wagnières G; Braichotte D; van den Bergh H
Arch Otolaryngol Head Neck Surg; 1997 Feb; 123(2):162-8. PubMed ID: 9046283
[TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein receptor pathway in the delivery of Photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumors?
Korbelik M
J Photochem Photobiol B; 1992 Jan; 12(1):107-9. PubMed ID: 1531856
[No Abstract] [Full Text] [Related]
18. Integral laser-photodynamic treatment of multifocal bladder carcinoma photosensitized by hematoporphyrin derivative.
Jocham D; Schmiedt E; Baumgartner R; Unsöld E
Eur Urol; 1986; 12 Suppl 1():43-6. PubMed ID: 2945724
[TBL] [Abstract][Full Text] [Related]
19. Photoradiation therapy of gynecologic malignancies.
Rettenmaier MA; Berman ML; DiSaia PJ; Burns RG; Berns MW
Gynecol Oncol; 1984 Feb; 17(2):200-6. PubMed ID: 6231229
[TBL] [Abstract][Full Text] [Related]
20. [Electron microscopic observation on human bladder cancer tissue after photodynamic therapy].
Zhou CN
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Jun; 10(3):176-8. PubMed ID: 2972405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
